Department of Gastroenterology, Hospital Universitario de La Princesa and Instituto de Investigación Sanitaria Princesa, IP, Madrid, Spain.
Am J Gastroenterol. 2013 Mar;108(3):433-40. doi: 10.1038/ajg.2012.430. Epub 2013 Jan 15.
The safety of thiopurines and anti-tumor necrosis factor-α (TNF-α) drugs during pregnancy remains controversial, as the experience with these drugs in this situation is limited. Our aim is to assess the safety of thiopurines and anti-TNF-α drugs for the treatment of inflammatory bowel disease (IBD) during pregnancy.
Retrospective, multicenter study in IBD patients. Pregnancies were classified according to the therapeutic regimens during pregnancy or during the 3 months before the conception: non-exposed group, pregnancies exposed to thiopurines alone (group A), and pregnancies exposed to anti-TNF-α drugs (group B). An unfavorable Global Pregnancy Outcome (GPO) was considered if pregnancy developed with obstetric complications in the mother and in the newborn.
A total of 187 pregnancies in the group A, 66 pregnancies in the group B, and 318 pregnancies in the non-exposed group were included. The rate of unfavorable GPO was different among the three groups (31.8% in non-exposed group, 21.9% in group A, and 34.8% in group B), being lower in pregnancies under thiopurines than among non-exposed (P = 0.01). The rate of pregnancy complications was similar among the three groups (27.7% in non-exposed, 20.9% in group A, and 30.3% in group B). The rate of neonatal complications was different among the three groups (23.3% in non-exposed group, 13.9% in group A, and 21.2% in group B), being lower in pregnancies under thiopurines than among non-exposed (P = 0.01). In the multivariate analysis, the treatment with thiopurines (odds ratio = 0.6; 95% confidence interval = 0.4-0.9, P = 0.02) was the only predictor of favorable GPO, whereas maternal age >35 years at conception was the only predictor of unfavorable GPO. The treatment with anti-TNF-α drugs was not associated with an unfavorable GPO.
The treatment with thiopurines and anti-TNF-α drugs does not seem to increase the risk of complications during pregnancy and does seem to be safe for the newborn.
在怀孕期间,硫嘌呤和抗肿瘤坏死因子-α(TNF-α)药物的安全性仍存在争议,因为在这种情况下,这些药物的经验有限。我们的目的是评估硫嘌呤和抗 TNF-α 药物治疗炎症性肠病(IBD)在怀孕期间的安全性。
对 IBD 患者进行回顾性、多中心研究。根据怀孕期间或受孕前 3 个月的治疗方案对妊娠进行分类:未暴露组、仅暴露于硫嘌呤的妊娠(A 组)和暴露于抗 TNF-α 药物的妊娠(B 组)。如果母亲和新生儿出现产科并发症,则认为总体不良妊娠结局(GPO)不良。
共纳入 A 组 187 例妊娠、B 组 66 例妊娠和未暴露组 318 例妊娠。三组的不良 GPO 发生率不同(未暴露组为 31.8%、A 组为 21.9%和 B 组为 34.8%),硫嘌呤组低于未暴露组(P=0.01)。三组妊娠并发症发生率相似(未暴露组为 27.7%、A 组为 20.9%和 B 组为 30.3%)。三组新生儿并发症发生率不同(未暴露组为 23.3%、A 组为 13.9%和 B 组为 21.2%),硫嘌呤组低于未暴露组(P=0.01)。多变量分析显示,硫嘌呤治疗(比值比=0.6;95%置信区间=0.4-0.9,P=0.02)是 GPO 良好的唯一预测因素,而受孕时母亲年龄>35 岁是 GPO 不良的唯一预测因素。抗 TNF-α 药物治疗与不良 GPO 无关。
硫嘌呤和抗 TNF-α 药物治疗似乎不会增加妊娠期间并发症的风险,并且似乎对新生儿是安全的。